Integra LifeSciences Holdings

Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company's neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care, such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment, and the precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices. The Tissue Technologies segment includes offerings such as skin and wound repair, bone and joint fixation implants in the upper and lower extremities, bone grafts, and nerve and tendon repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Integra LifeSciences posts solid Q4 results, eyes growth opportunities

Integra LifeSciences delivered strong financial performance in Q4 2022 and full-year 2022, showcasing operational resilience and efficiency amidst supply chain challenges and inflationary pressures.
The company's strategic focus on innovation, international growth, and operational excellence positions it well for sustainable growth in 2023, supported by new product launches and market expansion initiatives.
While facing challenges from supply chain disruptions and inflation, Integra's proactive approach to margin expansion, revenue growth, and strategic investments underscores its commitment to long-term value creation.
With a clear roadmap for 2023, including revenue growth targets, margin improvement strategies, and market expansion plans, Integra is poised to navigate challenges and capitalize on opportunities for continued success.

Integra LifeSciences exceeds Q1 expectations, eyes growth amid challenges

Integra LifeSciences demonstrated resilience and growth potential in Q1 2023, with strong segment performances and strategic initiatives.
While facing challenges like supply constraints and margin pressures, the company remains focused on operational efficiency and growth opportunities.
Reaffirmation of guidance, executive appointments, and proactive strategies position Integra well for future growth and market expansion.
Investors can expect improved performance in the second half, driven by new products, supply chain recovery, and strategic investments.

Integra LifeSciences reports Q2 challenges but shows resilience and growth

Integra LifeSciences navigated challenges from a product recall in Q2, showing resilience with solid profitability and growth in unaffected segments.
The company's strategic focus on returning critical technologies to the market, along with new leadership and financial initiatives, positions it for future success.
Despite challenges, Integra LifeSciences remains confident in regaining market share, sustaining growth momentum, and capitalizing on strategic opportunities.
Operational strengths, market performance, and proactive measures to address challenges underscore the company's resilience and growth potential.

Integra LifeSciences navigates Boston impact, eyes growth opportunities post-remediation

Integra LifeSciences faced challenges from the Boston facility recall but showed resilience with strong performance in key segments. The company is focused on growth opportunities post-Boston remediation and maintains a solid financial position. Analysts are optimistic about the company's ability to recover and grow post-recall.

Integra LifeSciences navigates challenges, eyes global growth opportunities

Integra LifeSciences faced challenges from the Boston recall impacting financials but showcased strengths in strategic product relaunches and divisional growth.
The company's performance metrics for 2023 were mixed, with declines in margins but strong cash flow generation. Opportunities lie in global growth catalysts like CereLink.
Looking ahead, Integra aims for revenue recovery post-Q1 headwinds, emphasizing international expansion and product recovery post-recall.

Integra LifeSciences reports strong Q1 results amidst operational challenges

Integra LifeSciences delivered solid Q1 results driven by revenue growth and successful acquisitions.
While facing challenges with the Boston plant audit and supply constraints, the company is focused on key priorities and opportunities for growth.
Maintaining financial stability with a clear plan to address leverage and uncertainties around product reintroduction.
Investors are closely monitoring the company's progress on key initiatives and leadership transition.

Integra LifeSciences excels in Q2 amidst compliance challenges and growth opportunities

Integra LifeSciences delivered a strong Q2 performance, focusing on operational improvements and compliance enhancements to drive long-term growth and sustainability.
While facing challenges such as revenue impacts from compliance investments and margin pressures, the company remains resilient with a strategic focus on market positioning and efficiency.
With updated guidance, successful acquisition integration, and a CEO search underway, Integra is poised to navigate challenges and capitalize on opportunities for future success.

Integra LifeSciences appoints new CEO amidst revenue challenges in Q3

Integra LifeSciences faced revenue challenges in Q3 2024 due to supply issues and compliance plan implementation. The company announced Mojdeh Poul as the new CEO to drive operational excellence and growth. Despite challenges, revenue diversification and financial stability were maintained, with a focus on future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. It operates under the Codman Specialty Surgical (CSS) and Tissue Technologies (TT) segments. The CSS segment includes technologies and instrumentation used for neurosurgery, neurocritical care, and otolaryngology. The TT segment focuses on complex wound surgery, surgical reconstruction, and peripheral nerve repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.

Integra (IART) notices recovery in procedure volumes leading to solid growth across most of its product portfolio in Q3.

Integra's (IART) Q3 Earnings Top, Gross Margin Declines

Integra LifeSciences Holdings Corporation. (NASDAQ:IART ) Q3 2022 Earnings Conference Call October 26, 2022 8:30 AM ET Company Participants Chris Ward - Senior Director, Investor Relations Jan De Witte - President & Chief Executive Officer Carrie Anderson - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG David Turkaly - JPM Vik Chopra - Wells Fargo Matthew Taylor - Jefferies Steve Lichtman - Oppenheimer Drew Ranieri - Morgan Stanley Richard Newitter - Truist Operator Hello and welcome to the Integra LifeScience Third Quarter 2022 Financial Results.

Integra LifeSciences Holdings Corporation (IART) Q3 2022 - Earnings Call Transcript

PRINCETON, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2022.

Integra LifeSciences Reports Third Quarter 2022 Financial Results

Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Integra LifeSciences (IART) Q3 Earnings Expected to Decline

PRINCETON, N.J., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, will release third quarter 2022 financial results on Wednesday, October 26, 2022, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET.

Integra LifeSciences to Host Third Quarter 2022 Financial Results Conference Call on October 26, 2022

PRINCETON, N.J., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today announced the appointment of Harvinder Singh as executive vice president and president of Integra's international business.

Integra LifeSciences Announces Key Executive Appointment

The report underscores the company's long-standing commitment to improving the health of patients and the planet. The report underscores the company's long-standing commitment to improving the health of patients and the planet.

Integra LifeSciences Publishes Its Inaugural ESG Report

Investors are optimistic about Integra's (IART) better-than-expected results and the continued demand for its products.

Here's Why Investors Should Retain Integra (IART) Stock for Now

Investors have punished Integra LifeSciences in FY22, most recently following the recall of its CereLink monitors. The market priced in the downside swiftly and with deep effect, helping shares find a 52-week low.

Integra LifeSciences: Wide Dislocation In Fundamentals Vs. Market Value

PRINCETON, N.J., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, announced today that it is participating in the following investor conferences:

Integra LifeSciences Announces Participation in Upcoming Investor Conferences

PRINCETON, N.J., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that Dr. Richard Caruso, founder and former chairman and CEO of Integra LifeSciences passed away over the past weekend.

Integra LifeSciences Announces the Passing of Dr. Richard Caruso, Founder and Former Chairman and CEO

Integr's (IART) year-over-year growth in both the CSS and Tissue Technology segments buoys optimism.

Integra (IART) Q2 Earnings Top, 2022 Adjusted EPS View Cut

Integra LifeSciences Holdings Corporation (NASDAQ:IART ) Q2 2022 Earnings Conference Call July 27, 2022 8:30 AM ET Company Participants Chris Ward - Senior Director, Investor Relations Jan De Witte - President & Chief Executive Officer Glenn Coleman - Chief Operating Officer Carrie Anderson - Chief Financial Officer Conference Call Participants Steve Lichtman - Oppenheimer Vik Chopra - Wells Fargo Ryan Zimmerman - BTIG Joanne Wuensch - Citi Sam Brodovsky - Truist Matt Miksic - Barclays Craig Bijou - Bank of America Jayson Bedford - Raymond James Drew Ranieri - Morgan Stanley Operator Good day, and welcome to the Integra LifeSciences Second Quarter 2022 Financial Results Conference Call. Today's conference is being recorded.

Integra LifeSciences Holdings Corporation (IART) CEO Jan De Witte on Q2 2022 Results - Earnings Call Transcript

Integra (IART) delivered earnings and revenue surprises of 2.50% and 0.83%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Integra LifeSciences (IART) Tops Q2 Earnings and Revenue Estimates

PRINCETON, N.J., July 27, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2022.

Integra LifeSciences Reports Second Quarter 2022 Financial Results

PRINCETON, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced the appointment of Renee Lo to its board of directors as an independent director to fill an existing vacancy, effective July 18, 2022.

Integra LifeSciences Appoints Renee Lo as Director

PRINCETON, N.J., July 01, 2022 (GLOBE NEWSWIRE) -- ) Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, will release second quarter 2022 financial results on Wednesday, July 27, 2022, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET.

Integra LifeSciences to Host Second Quarter 2022 Financial Results Conference Call on July 27, 2022

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Integra LifeSciences (IART) is a Top Value Stock for the Long-Term

Integra's (IART) international sales in CSS grow led by the strong performance of CereLink in Europe and growth in Asia.

Integra (IART) Gains From Innovation Amid Cost Constraints

Integra's (IART) updated 2022 financial guidance calls for strong year-over-year organic growth.

Integra (IART) Q1 Earnings Top Estimates, Margins Expand

Edwards Lifesciences

IART vs. EW: Which Stock Is the Better Value Option?

Integra LifeSciences Holdings Corp (NASDAQ: IART) reported Q1 FY22 sales of $376.6 million, +4.6% Y/Y on a reported basis and 5.6% organic, beating the consensus of $362.04 million. Adjusted EPS stood at $0.74, ahead of The Street estimate of $0.68.

Integra LifeSciences Posts Street Beating Earnings, Backs FY22 Guidance

Integra LifeSciences Holdings Corporation (NASDAQ:IART ) Q1 2022 Earnings Conference Call April 27, 2022 8:30 AM ET Company Participants Jan De Witte – President & Chief Executive Officer Glenn Coleman – Chief Operating Officer Carrie Anderson – Chief Financial Officer Christopher Ward – Senior Director of Investor Relations Conference Call Participants Steven Lichtman – Oppenheimer & Company Robbie Marcus – JPMorgan Ryan Zimmerman – BTIG Vik Chopra – Wells Fargo Craig Bijou – Bank of America David Turkaly – JMP Securities Rich Newitter – Truist Matt Miksic – Credit Suisse Frank Camma – Jefferies Jayson Bedford – Raymond James Operator Good day, ladies, and gentlemen. You are on hold for today's conference call.

Integra LifeSciences Holdings Corporation (IART) CEO Jan De Witte on Q1 2022 Results - Earnings Call Transcript

Integra (IART) delivered earnings and revenue surprises of 8.82% and 3.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Integra LifeSciences (IART) Tops Q1 Earnings and Revenue Estimates

PRINCETON, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2022.

News for Integra LifeSciences Holdings Stock (IART)